# A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

> **NCT05519670** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 72 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Niraparib Oral Product

## Key facts

- **NCT ID:** NCT05519670
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519670, "A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05519670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*